Inventiva S.A./€IVA
05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX
About Inventiva S.A.
Inventiva S.A. is a clinical-stage biopharmaceutical company based in France, focused on developing oral small molecule therapies for the treatment of diseases with unmet medical needs, particularly in the areas of fibrosis, lysosomal storage disorders, and oncology. The company’s leading product candidate is lanifibranor, which is currently in clinical trials for the treatment of non-alcoholic steatohepatitis (NASH). Founded in 2012, Inventiva leverages its proprietary technology platform to identify and develop innovative compounds. The company's research and development operations are concentrated in Daix, France. Inventiva’s competitive strength lies in its robust pipeline and strategic collaborations with partners in the pharmaceutical industry. Sources:
1. https://inventivapharma.com/en/
2. https://ir.inventivapharma.com/
3. https://www.wallstreet-online.de/nachricht/14672309-inventiva-reports-financial-results-quarter-ended-september-30-2021
Ticker
€IVA
Sector
Primary listing
PAR
Employees
73
Headquarters
Website
Inventiva S.A. Metrics
BasicAdvanced
€631m
-
-€1.90
0.88
-
Price and volume
Market cap
€631m
Beta
0.88
52-week high
€6.16
52-week low
€2.59
Average daily volume
50k
Financial strength
Current ratio
3.159
Quick ratio
1.408
Long term debt to equity
-696.238
Total debt to equity
-809.515
Interest coverage (TTM)
-3.96%
Profitability
EBITDA (TTM)
-138.856
Gross margin (TTM)
99.67%
Net profit margin (TTM)
-5,237.95%
Operating margin (TTM)
-2,085.70%
Effective tax rate (TTM)
-0.01%
Revenue per employee (TTM)
€90,000
Management effectiveness
Return on assets (TTM)
-45.08%
Return on equity (TTM)
523.99%
Valuation
Price to revenue (TTM)
84.132
Price to book
-20.6
Price to tangible book (TTM)
-20.47
Price to free cash flow (TTM)
-5.411
Free cash flow yield (TTM)
-18.48%
Free cash flow per share (TTM)
-0.563
Growth
Revenue change (TTM)
-43.76%
Earnings per share change (TTM)
-38.48%
3-year revenue growth (CAGR)
-27.92%
10-year revenue growth (CAGR)
-0.88%
3-year earnings per share growth (CAGR)
13.13%
10-year earnings per share growth (CAGR)
7.98%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
FAQs